Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Protalix BioTherapeutics, Inc.

http://www.protalix.com

Latest From Protalix BioTherapeutics, Inc.

Chiesi Returns To Respiratory Roots With Affibody Pact

A busy start to the year sees the Italian firm adding to its respiratory portfolio by gaining access to the Swedish biotech’s investigational inhaled treatments.

Respiratory Deals

EMA Backs Approval For Eight New Drugs But Rejects Lagevrio For COVID-19

Janssen’s Akeega is among the latest drugs that the European Medicines Agency says should be approved for use in the EU. Meanwhile, MSD/Ridgeback Biotherapeutics plan to appeal the agency’s rejection of their COVID-19 treatment.

Approvals Europe

EU Decision Time For Zejula/Zytiga Combo Therapy, Vadadustat & Other Drugs

The European Medicines Agency’s human medicines committee, the CHMP, is this week deciding whether to back the approval of a number of new drugs.

Europe Approvals

Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

United States US FDA Performance Tracker
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Synthesis Technologies, Production Processes
    • Transgenics
  • Other Names / Subsidiaries
    • Protalix Ltd.
UsernamePublicRestriction

Register